CTOR

1.10% -0.0062

Handel nachbörslich: .56 0.004 +0.72%

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1074)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	0.556	52.27M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	17.44	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.94	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.08	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.94	26.32B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-23	Hochstufung	Maxim Group	Hold → Buy
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView

TradingKey - TradingKey

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

CTOR|Citius Oncology Inc|Price:0.541|Chg%:-0.037 - TradingKey

Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr

Citius Oncology expands sales team for LYMPHIR launch - Investing.com

Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com UK

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - PR Newswire

Citius Oncology Inc. (CTOR) Q2 2026 Earnings: Significant EPS Miss with No Reported RevenueProfit Inflection Point - dars.gov.et

Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan

Citius Oncology (CTOR) Registration filing Summary - Quartr

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

CTOR Q1 2026 Earnings: Significant EPS Miss Despite Stock RallyProfit Recovery Report - dars.gov.et

CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et

CTOR Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Company Posts Wider Than Expected LossOne-Time Gain Impact - dars.gov.et

Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView

Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView

Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

CTOR Forecast — Price Target — Prediction for 2027 - TradingView

Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology (CTOR) Edges Higher as Shares Approach Resistance at $0.73Volume Rate Change - dars.gov.et

Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey

CTOR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; No Revenue ReportedEPS Growth Rate - DonanımHaber

CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill

Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey

CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com

Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com

Citius Oncology Inc. (CTOR) Edges Higher as Shares Test Key Resistance LevelsBox Spread - dars.gov.et

CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com

Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com

[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan

Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan

Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView

[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan

Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart

Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart

Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks

Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan

Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan

Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus

Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR